Krystal Biotech, Inc. (KRYS) company profile
Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –
About Krystal Biotech
Biological Products, (No Diagnostic Substances), SIC 2836
The company discovers, manufactures, and commercializes redosable genetic medicines designed to treat rare and debilitating conditions with substantial unmet medical needs. Utilizing a proprietary gene therapy platform engineered from herpes simplex virus-1, it produces targeted therapies that can be administered non-invasively at healthcare facilities or in home environments. Its principal commercial offering is Vyjuvek, an approved topical treatment for wounds caused by dystrophic epidermolysis bullosa. In addition to developing pipeline candidates for respiratory, dermatological, and ophthalmic diseases, the business addresses aesthetic conditions through its dedicated subsidiary, primarily serving pediatric and adult patients affected by serious genetic disorders.
The company operates two commercial-scale manufacturing sites situated in Pennsylvania, from which it distributes gene therapies internationally. Commercial activities are conducted directly across the United States, Japan, and major European markets including Germany and France, alongside planned expansions into broader Western European territories. It further distributes products via regional specialty partner networks in Central and Eastern Europe, the Middle East, and Israel. The provided text mentions no details regarding the location of the corporate headquarters.
Summary of the business section of Krystal Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Krystal Biotech, Inc.
- Headquarters
- Pittsburgh, PA
- Address
- 2100 Wharton Street, Suite 701 15203
- Phone
- (412) 586-5830
- Website
- www.krystalbio.com
- Employees
- 295, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Pittsburgh
Stock & identifiers
- Ticker
- KRYS
- Exchange
- Nasdaq
- IPO date
- Sep 20, 2017
- Shares outstanding
- 30M, Jul 28, 2026
- Public float
- $3.50B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1711279
- CUSIP
- 501147102
- ISIN
- US5011471027
- FIGI
- BBG00HDGRHH7
- Share class FIGI
- BBG00HDGRHJ5
- LEI
- 549300YONUY68210OE41
- EIN
- 82-1080209
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Krish S. Krishnan | President and CEO, Director | 1,567,863 |
| Suma Krishnan | President, R&D, Director | 1,512,362 |
| John Charles Thomas | EVP, General Counsel | 1,000 |
| Laurent Louis Jean Goux | EVP, Head of International | 919 |
| Kathryn Romano | Chief Accounting Officer | 22,366 |
| Dino A. Rossi | Director | 46,500 |
| Daniel Janney | Director | 76,409 |
| Catherine Mazzacco | Director | – |
| Julian S. Gangolli | Director | 20,000 |
| Christopher Mason | Director | – |
| Everett Rand Sutherland | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $10.44M | $22.80M | $4.60M | $411 | $120 |
| FY2024 | $15.60M | $19.83M | $5.65M | $283 | $114 |
| FY2023 | $6.22M | $11.69M | $2.89M | $224 | $115 |
| FY2022 | $3.26M | $4.30M | $2.85M | $143 | $111 |
| FY2021 | $7.35M | $6.80M | $5.88M | $126 | $125 |
| FY2020 | $763.77K | $763.77K | $1.30M | $108 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Krish S. Krishnan Chair and Chief Executive Officer | $846.17K | $682.40K | $4.10M | $4.68M | $134.00K | $10.44M | -33% |
| Kathryn A. Romano Chief Accounting Officer | $437.50K | $223.26K | $394.35K | $1.19M | $14.00K | $2.26M | -26% |
| Suma M. Krishnan President, R&D | $677.50K | $414.92K | $2.87M | $2.97M | $14.00K | $6.95M | -16% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 20, 2017
- Offer price
- $10.00
- Securities offered
- 3,960,000
- Gross proceeds
- $39.60M
- Exchange
- Nasdaq
- First trading day
- Sep 20, 2017
- First-day close
- $10.64+6.4%
- Lock-up ends (est.)
- Mar 19, 2018
“The initial public offering price of our common stock is $10.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 11, 2026, we had 295 full-time employees, primarily engaged in research and development, pre-clinical and clinical trials, manufacturing VYJUVEK and our pipeline product candidates, commercial activities for VYJUVEK in the United States, the European Union, and Japan, regulatory matters, strategic business development, finance and other t”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 26, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 20, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 19, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?